Literature DB >> 23817820

Sex and mortality of hospitalized adults after admission to an intensive care unit.

Jed Lipes1, Louay Mardini, Dev Jayaraman.   

Abstract

BACKGROUND: After admission to intensive care, women have higher mortality rates than do men. The reasons for the greater mortality in women are not fully understood.
OBJECTIVE: To determine if increased mortality in women was due to delays in the recognition of critical illness or to delays in timely admission to intensive care.
METHODS: A total of 241 consecutive admissions to intensive care from medical and surgical units during a 12-month period were analyzed retrospectively. Patients' demographics, illness severity, and delay between the time the patients would have fulfilled criteria for calling a medical emergency team and consultation with and admission to intensive care were analyzed.
RESULTS: Delay from fulfillment of criteria for calling a medical emergency team and consultation with intensive care and from consultation to admission to intensive care did not differ between sexes. Despite similar delays in admission to intensive care, women had a higher 30-day mortality than did men (44.9% vs 30.5%; P = .02). The increased mortality was more pronounced in the medical patients (53% vs 34%; P = .02). Multivariate analysis of mortality data yielded a mortality odds ratio of 0.35 (95% CI, 0.16-0.74) for men, significantly different from values for women (P = .006).
CONCLUSION: After admission to intensive care from medical or surgical units, women had higher mortality rates than did men, and the difference was more pronounced in medical patients. The difference in mortality between sexes was not explained by delayed recognition of critical illness or delayed admission to intensive care.

Entities:  

Mesh:

Year:  2013        PMID: 23817820     DOI: 10.4037/ajcc2013225

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  7 in total

1.  Physical Function Trajectories in Survivors of Acute Respiratory Failure.

Authors:  Sheetal Gandotra; James Lovato; Douglas Case; Rita N Bakhru; Kevin Gibbs; Michael Berry; D Clark Files; Peter E Morris
Journal:  Ann Am Thorac Soc       Date:  2019-04

2.  Altering aspects of mitochondrial quality to improve musculoskeletal outcomes in disuse atrophy.

Authors:  Megan E Rosa-Caldwell; Seongkyun Lim; Wesley S Haynie; Lisa T Jansen; Lauren C Westervelt; Madeline G Amos; Tyrone A Washington; Nicholas P Greene
Journal:  J Appl Physiol (1985)       Date:  2020-09-17

3.  The oestrous cycle and skeletal muscle atrophy: Investigations in rodent models of muscle loss.

Authors:  Megan E Rosa-Caldwell; Marie Mortreux; Ursula B Kaiser; Dong-Min Sung; Mary L Bouxsein; Kirsten R Dunlap; Nicholas P Greene; Seward B Rutkove
Journal:  Exp Physiol       Date:  2021-10-18       Impact factor: 2.858

4.  Use of photoplethysmography to predict mortality in intensive care units.

Authors:  Kelser de Souza Kock; Jefferson Luiz Brum Marques
Journal:  Vasc Health Risk Manag       Date:  2018-10-31

Review 5.  Muscle metabolism and atrophy: let's talk about sex.

Authors:  Megan E Rosa-Caldwell; Nicholas P Greene
Journal:  Biol Sex Differ       Date:  2019-08-28       Impact factor: 5.027

6.  Mitochondrial aberrations during the progression of disuse atrophy differentially affect male and female mice.

Authors:  Megan E Rosa-Caldwell; Seongkyun Lim; Wesley S Haynie; Jacob L Brown; David E Lee; Kirsten R Dunlap; Lisa T Jansen; Tyrone A Washington; Michael P Wiggs; Nicholas P Greene
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-09-29       Impact factor: 12.910

7.  Female mice may have exacerbated catabolic signalling response compared to male mice during development and progression of disuse atrophy.

Authors:  Megan E Rosa-Caldwell; Seongkyun Lim; Wesley A Haynie; Jacob L Brown; John William Deaver; Francielly Morena Da Silva; Lisa T Jansen; David E Lee; Michael P Wiggs; Tyrone A Washington; Nicholas P Greene
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-03-05       Impact factor: 12.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.